This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Expedia, Starbucks: New Targets, Estimates

Also see: Vertex, AIG: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Automatic Data Processing (ADP) estimates, target adjusted at Citigroup. Shares of ADP now seen reaching $58. Estimates adjusted through 2013. Mixed quarter, but strong FY12 guidance.

Celgene (CELG - Get Report) estimates, target increased at UBS. Shares of CELG now seen reaching $71. Estimates also increased on strong beat and raise in 2Q. Buy rating.

Cerner (CERN) estimates, target increased at Goldman. CERN estimates were raised through 2013. Company is seeing higher bookings and is expanding margins. Buy rating and new $80 price target.

Cerner estimates, target increased at UBS. Shares of CERN now seen reaching $65. Estimates also increased on large bookings and faster growth forecasts. Neutral rating.

CME Group (CME) estimates, target higher at UBS. Shares of CME now seen reaching $325. Estimates also raised on strong 2Q and attractive growth profile. Buy rating.

Expedia (EXPE - Get Report) estimates, target raised at Citigroup. Shares of EXPE now seen reaching $36, according to Citigroup. Estimates also increased on solid 2Q and stable US market share. Buy rating.

Expedia estimates, target increased at UBS. Shares of EXPE now seen reaching $33, UBS said. Estimates also increased on Q2 beat and conservative guidance. Neutral rating.

Graco (GGG) estimates, target reduced at Goldman. Shares of GGG now seen reaching $47.50, according to Goldman Sachs. Estimates also cut, as the company is realizing a slower demand recovery. Sell rating.

Goodyear (GT) estimates raised at Citigroup through 2012. Q2 beat and stronger price/mix. Maintain $22 price target and Buy rating.

Starwood Hotels (HOT - Get Report) estimates lowered at UBS. HOT estimates lowered through 2012. Valuation call. Maintain $70 price target and Buy rating.

Interpublic (IPG - Get Report) estimates, target lowered at Goldman. IPG estimates were cut through 2013. Lower sales are cutting into margins. Neutral rating and new $12 price target.

KLA-Tencor (KLAC - Get Report) estimates lowered at UBS through 2012. Expect 2H weakness. Maintain $49.50 price target and Buy rating.

Life Technologies (LIEF) estimates, target lowered at UBS. Shares of LIFE now seen reaching $55. Estimates also lowered on organic revenue and EPS misses. Buy rating.

MetLife (MET) estimates raised at UBS through 2011. International results solid, especially top line trends. Maintain $60 price target and Buy rating.

Motorola (MMI) estimates, target cut at UBS. Shares of MMI now seen reaching $31, according to UBS. Estimates also lowered as new product launches need to "stick." Buy rating.

Noble Energy (NBL) numbers raised at Goldman. Shares of NBL now seen reaching $126, according to Goldman Sachs. Estimates also increased, given higher production and free cash flow results. Buy rating.

NetLogic Microsystem (NETL) estimates, target lowered at UBS. Shares of NETL now seen reaching $44. Estimates also lowered as soft macro weighs on growth outlook. Buy rating.

Potash (POT) estimates, target boosted at Goldman. Shares of POT now seen reaching $67. Estimates also upped, to match the company's new guidance. Buy rating.

Sprint Nextel (S) estimates, target cut at UBS. Shares of S now seen reaching $5, according to UBS. Estimates also lowered on weak postpaid adds and margins in 2Q. Neutral rating.

Starbucks (SBUX - Get Report) estimates, target raised at UBS. Shares of SBUX now seen reaching $47. Estimates also raised on higher medium term revenue and free cash flow. Buy rating.

Strayer (STRA) estimates, target reduced at Goldman. Shares of STRA now seen reaching $134, according to Goldman Sachs. Estimates also lowered, given lower enrollment rates. Neutral rating.

Teradyne (TER) estimates lowered at UBS through 2011, UBS said. Working through a normal downcycle. Maintain $16 price target and Neutral rating.

End of report.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CELG $119.52 0.00%
EXPE $107.07 0.00%
GTE $2.89 0.00%
HOT $82.27 0.00%
KLAC $57.26 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs